Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Allogene Therapeutics, Inc. (ALLO)

10.26   -0.51 (-4.74%) 11-28 16:00
Open: 10.64 Pre. Close: 10.77
High: 10.87 Low: 9.95
Volume: 1,322,024 Market Cap: 1,480(M)

Technical analysis

as of: 2022-11-28 4:37:49 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 12.96     One year: 15.14
Support: Support1: 9.46    Support2: 8.46
Resistance: Resistance1: 11.1    Resistance2: 12.96
Pivot: 9.9
Moving Average: MA(5): 10.52     MA(20): 9.92
MA(100): 12.3     MA(250): 11.23
MACD: MACD(12,26): -0.1     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 77.3     %D(3): 83.2
RSI: RSI(14): 50.1
52-week: High: 19.11  Low: 6.42
Average Vol(K): 3-Month: 1,796 (K)  10-Days: 1,592 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ALLO ] has closed below upper band by 35.1%. Bollinger Bands are 24.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.89 - 10.94 10.94 - 10.99
Low: 9.83 - 9.89 9.89 - 9.93
Close: 10.18 - 10.27 10.27 - 10.34

Company Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Headline News

Sun, 27 Nov 2022
Montréal's Rising Star Izzy-S Returns With "Allo c'est qui?" Single: Stream - HotNewHipHop

Fri, 25 Nov 2022
‘Allo, Beirut?’ exhibition reconnects to forgotten past of Lebanon’s capital - The National

Fri, 11 Nov 2022
ALLO recognized for work in hiring veterans - KSNB

Wed, 09 Nov 2022
'Allo! Allo! Will Neyland attend tenth anniversary twinning weekend? - Yahoo News UK

Thu, 03 Nov 2022
Allo commits to continued support of employees serving in Guard, Reserves - North Platte Post

Tue, 01 Nov 2022
Bukalapak, Allo Fresh Collaboration Still Has No Visible Results | D-Insights - Katadata

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 144 (M)
% Held by Insiders 8.241e+007 (%)
% Held by Institutions 29.7 (%)
Shares Short 27,590 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -2.975e+008
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -126
Return on Assets (ttm) 707.6
Return on Equity (ttm) -19.9
Qtrly Rev. Growth 247000
Gross Profit (p.s.) 0
Sales Per Share -61.99
EBITDA (p.s.) -3.07949e+008
Qtrly Earnings Growth -2.3
Operating Cash Flow 0 (M)
Levered Free Cash Flow -204 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -4.3
Price to Book value 0
Price to Sales -0.17
Price to Cash Flow 1.17

Stock Dividends

Dividend 0
Forward Dividend 3.096e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.